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Abstract
Papillary ﬁbroelastomas are rare benign tumours of the endocardium, accounting for the most common primary valvular tumours of the
heart. They typically originate from left-sided heart valves, whereas pulmonary valve involvement is anecdotal. They rarely cause valvular
dysfunction, but they can cause turbulent ﬂow and thrombus formation with consequent cerebral, retinal, coronary and pulmonary
embolic disease and obstruction. We present here the case of a 56-year old man who was referred to our institution with an accidental
ﬁnding, at transthoracic echocardiogram, of a mobile, pedunculated mass on the pulmonary valve, conﬁrmed at cardiac magnetic reson-
ance. He underwent surgical removal of the mass through median sternotomy with complete sparing of the valve. The postoperative
course was unremarkable. Histopathological examination conﬁrmed that the mass was a papillary ﬁbroelastoma.
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INTRODUCTION
Primary cardiac tumours are a very rare pathology, with an inci-
dence of 0.0017–0.33% at autopsy studies. The most common
are myxomas (30%), followed by lipomas (10%) and papillary
ﬁbroelastomas (PFEs) (8%) [1]. These latter are rare benign
tumours of the endocardium and represent the most common
primary valvular tumours of the heart. Their incidence has been
estimated to be between 0.00017 and 0.033% at autopsy and
0.019% in clinical series [2].
PFEs consist of small, papillary, pedunculated and avascular
tumours, covered by a single layer of endothelium, containing
variable amounts of elastic ﬁbrils arranged in whorls in a hyaline
stroma [3]. They typically originate from the endocardium of left-
sided heart valves (95%), more frequently on the aortic (44.5%)
than on the mitral valve (36.4%), whereas pulmonary valve (PV)
involvement is rare, comprising 8% of the cases. Involvement of
the tricuspid valve is less commonly reported. PFEs usually occur
as a single tumour; however, rare cases of multiple ﬁbroelastomas
have been reported [4]. The mean age of diagnosis is 60 years [3].
It has been hypothesized that PFEs arise from the haemo-
dynamic stress of blood ﬂow across the endocardium, with
endothelial damage followed by the deposit of ﬁbrin ﬁbres with
thrombosis and organization [3]. They have also possibly been
listed as true neoplasm, hamartomas and extensions of Lambl’s
excrescences. Infectious processes have been related to PFEs as
a cytomegalovirus has been recovered from the tumour, suggest-
ing a possible viral induction [5]. Histologically, PFEs consist of a
dense ﬁbroelastin core with surrounding loose connective tissue
covered by a superﬁcial endothelial layer. This connective tissue
contains a mucopolysaccharide acid matrix, smooth muscle cells,
collagen, elastin ﬁbres, proteoglycans, ﬁbroblasts, macrophages
and dendritic cells. Occasionally, cysts and areas of a haemor-
rhage are found. Differential diagnoses include other tumours
(myxomas and lipomas), thrombi and bacterial vegetations [5].
CASE REPORT
We present the case of a 56-year old, asymptomatic man who was
referred to our institution with an accidental ﬁnding, at a routine
transthoracic echocardiogram (Fig. 1A), of a pedunculated mass on
the PV 13 × 9 mm in dimension. He was examined with a trans-
oesophageal echocardiogram (Fig. 1B) that conﬁrmed the presence
of a mobile echogenic mass attached to the ventricular side of the
PV anterior leaﬂet, likely to be a ﬁbroelastoma. The PV itself was
functionally normal. No masses were visualized on the other
valves. In addition, no masses were seen in the right atrium, inferior
and superior vena cavae. A cardiac magnetic resonance (CMR) was
also performed with the report of a mobile, non-calciﬁed spherical
structure attached to the ventricular surface of the anterior leaﬂet
of the PV, with intermediate signal intensity on a steady-state free
precession sequence and high signal on T2-weighted sequences
(Fig. 1C and D).
Considering the clinical condition, the age of the patient and
the characteristics of the mass and its extreme mobility, we
decided to remove it. Through median sternotomy, on cardiopul-
monary bypass, on a beating heart with no aortic cross-clamping,
we performed the excision of a gelatinous, pedunculated mass
(Fig. 2A-B-C), opening the pulmonary trunk longitudinally, with
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complete sparing and shaving of the PV. The postoperative course
was unremarkable. The patient was discharged on the 6th day in
good general condition. Histopathological examination conﬁrmed
that the mass was a PFE (Fig. 2D).
DISCUSSION
The PFE is a benign tumour with a low tendency to grow. It rarely
causes valvular dysfunction [5]. However, many authors agree that
PFEs have the potential to cause turbulent ﬂow and thrombus for-
mation, as the tumour surface comprises multiple projections and
makes it highly friable as well as susceptible to clot formation [4];
consequently cerebral, retinal, coronary and pulmonary embolic
disease and obstruction have been reported [3].
Because of this potential for embolic complications, the most
appropriate therapy for PFEs is surgical resection. Recurrence
after surgical excision has yet to be reported [3–4]. Surgery is
advocated for left-sided tumours, but much less is known on the
management of right-sided ones. Concerning PV PFEs, only 43
cases have been listed by Godwa et al. since 1856, autopsy series
included. In 1991, Edwards et al. listed out, of 56 primary cardiac
tumours, only 13 lesions affecting PV since 1931.
We know that PV PFEs are mostly asymptomatic, but they can
be related to complications such as pulmonary embolism.
Embolization of thrombi or tumour fragments into the pulmon-
ary vessels has been reported [3]. In general, there is insufﬁcient
clinical experience to produce written protocols. However, we
know that surgical treatment involves a relatively simple excision
of the mass with excellent prognosis. Gowda et al. [3] documen-
ted a 50% PFE-related mortality rate, from either systemic em-
bolization or outﬂow obstruction, in patients who did not
undergo curative resection. Again, most of these patients had
left-sided lesions, so it is impossible to extrapolate data solely
concerning right-sided ones.
A typical diagnosis is incidental by trans-thoracic echocardiog-
raphy. A subsequent transoesophageal scanning can be useful to
determine the relation between the mass and the adjacent struc-
tures. Moreover, a CMR can have a leading role regarding the
anatomic and tissue characterization and the functional aspect
of the mass.
In conclusion, we believe that the best treatment for a PV PFE
is surgical resection, which can efﬁciently be performed with
respect to the integrity of the valve’s leaﬂet, on-pump, with no
need for aortic cross-clamp, with a cardiopulmonary bypass to
drain the heart chambers. The use of long-term anticoagulation
can be advocated for elderly patients with contraindications for
surgery [3].
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Figure 1: (A and B) Transthoracic echocardiography and transoesophageal echocardiography showing the mass over the pulmonary valve (PV) (arrow). (C) Cardiac
magnetic resonance (CMR) (Discovery 450, General Electric Healthcare, 1.5 T Unit, Milwaukee, WI, USA) scan images showing a spherical mass (arrow), 8×7.5 mm
in dimension, attached to the anterior leaﬂet of the PV. The papillary ﬁbroelastoma (PFE) appears hypointense compared with heart chambers in this steady-state
free precession sequence. (D) CMR highlighting the PFE (arrow) which is hyperintense in black-blood T2-weighted coronal section.
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Figure 2: (A) Surgical vision of the papillary ﬁbroelastoma (PFE) adhered to the ventricular side of the anterior leaﬂet of the pulmonary valve (PV). (B) Surgical
view of the ventricular side of the anterior PV leaﬂet after the removal of the mass. (C) Vision of the mass after surgical removal: it is rounded in shape, peduncu-
lated, semi-elastic in consistency, 1.3 cm in length. (D) Histological sample with a dense ﬁbroelastin core surrounded by loose connective tissue covered by a
superﬁcial endothelial layer comprehensive of mucopolysaccharide acid matrix, smooth muscle cells, collagen, elastin ﬁbres, proteoglycans and ﬁbroblasts.
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